MRX-6038

MRX-6038 is a novel small molecule antibiotic that acts as a leucyl-tRNA synthetase inhibitor. It demonstrates potent in vitro and in vivo activity against Mycobacterium abscessus (Mab), an emerging nontuberculous mycobacterial pathogen associated with severe pulmonary infections, particularly in vulnerable populations such as those with cystic fibrosis or immunosuppression. MRX-6038 inhibits the growth of both extracellular and intracellular M. abscessus, showing efficacy comparable to or greater than established therapies like linezolid and clarithromycin in preclinical models. The drug also exhibits synergistic effects when combined with macrolides such as clarithromycin or azithromycin, without evidence of antagonism with other anti-Mab agents. MRX-6038 is the active metabolite of the oral prodrug MRX-5, which has completed Phase 1 clinical trials for non-tuberculous mycobacterial infections[1][3][6][7].